Search

Your search keyword '"Kassi, Eva"' showing total 546 results
Start Over Author "Kassi, Eva"
546 results on '"Kassi, Eva"'

5. What is the role of CHCHD2 in adrenal tumourigenesis?

Author

Karapanagioti, Angeliki, Nasiri-Ansari, Narjes, Moustogiannis, Athanasios, Trigas, George C., Zografos, Georgios, Aggeli, Chrysanthi, Kyriakopoulos, Georgios, Choreftaki, Theodosia, Philippou, Anastassios, Kaltsas, Gregory, Kassi, Eva, and Angelousi, Anna

Published
2023
Full Text
View/download PDF

7. Integrated omics analysis for characterization of the contribution of high fructose corn syrup to non-alcoholic fatty liver disease in obesity

Author

Papadopoulos, Grigorios, Legaki, Aigli-Ioanna, Georgila, Konstantina, Vorkas, Panagiotis, Giannousi, Eirini, Stamatakis, George, Moustakas, Ioannis I., Petrocheilou, Maria, Pyrina, Iryna, Gercken, Bettina, Kassi, Eva, Chavakis, Triantafyllos, Pateras, Ioannis S., Panayotou, George, Gika, Helen, Samiotaki, Martina, Eliopoulos, Aristides G., and Chatzigeorgiou, Antonios

Published
2023
Full Text
View/download PDF

13. Anti-osteoporotic treatments in the era of non-alcoholic fatty liver disease:friend or foe

Author

Chondrogianni, Maria Eleni, Kyrou, Ioannis, Androutsakos, Theodoros, Flessa, Christina-Maria, Menenakos, Evangelos, Chatha, Kamaljit Kaur, Aranan, Yekaterina, Papavassiliou, Athanasios G, Kassi, Eva, Randeva, Harpal S, Chondrogianni, Maria Eleni, Kyrou, Ioannis, Androutsakos, Theodoros, Flessa, Christina-Maria, Menenakos, Evangelos, Chatha, Kamaljit Kaur, Aranan, Yekaterina, Papavassiliou, Athanasios G, Kassi, Eva, and Randeva, Harpal S

Abstract

Over the last years non-alcoholic fatty liver disease (NAFLD) has grown into the most common chronic liver disease globally, affecting 17-38% of the general population and 50-75% of patients with obesity and/or type 2 diabetes mellitus (T2DM). NAFLD encompasses a spectrum of chronic liver diseases, ranging from simple steatosis (non-alcoholic fatty liver, NAFL) and non-alcoholic steatohepatitis (NASH; or metabolic dysfunction-associated steatohepatitis, MASH) to fibrosis and cirrhosis with liver failure or/and hepatocellular carcinoma. Due to its increasing prevalence and associated morbidity and mortality, the disease-related and broader socioeconomic burden of NAFLD is substantial. Of note, currently there is no globally approved pharmacotherapy for NAFLD. Similar to NAFLD, osteoporosis constitutes also a silent disease, until an osteoporotic fracture occurs, which poses a markedly significant disease and socioeconomic burden. Increasing emerging data have recently highlighted links between NAFLD and osteoporosis, linking the pathogenesis of NAFLD with the process of bone remodeling. However, clinical studies are still limited demonstrating this associative relationship, while more evidence is needed towards discovering potential causative links. Since these two chronic diseases frequently co-exist, there are data suggesting that anti-osteoporosis treatments may affect NAFLD progression by impacting on its pathogenetic mechanisms. In the present review, we present on overview of the current understanding of the liver-bone cross talk and summarize the experimental and clinical evidence correlating NAFLD and osteoporosis, focusing on the possible effects of anti-osteoporotic drugs on NAFLD.

Published
2024

14. Stress-Related Roles of Exosomes and Exosomal miRNAs in Common Neuropsychiatric Disorders.

Author

Chamakioti, Myrsini, Chrousos, George P., Kassi, Eva, Vlachakis, Dimitrios, and Yapijakis, Christos

Subjects
HUNTINGTON disease, ALZHEIMER'S disease, NEUROBEHAVIORAL disorders, BIPOLAR disorder, MENTAL illness
Abstract

Exosomes, natural nanovesicles that contain a cargo of biologically active molecules such as lipids, proteins, and nucleic acids, are released from cells to the extracellular environment. They then act as autocrine, paracrine, or endocrine mediators of communication between cells by delivering their cargo into recipient cells and causing downstream effects. Exosomes are greatly enriched in miRNAs, which are small non-coding RNAs that act both as cytoplasmic post-transcriptional repression agents, modulating the translation of mRNAs into proteins, as well as nuclear transcriptional gene activators. Neuronal exosomal miRNAs have important physiologic functions in the central nervous system (CNS), including cell-to-cell communication, synaptic plasticity, and neurogenesis, as well as modulating stress and inflammatory responses. Stress-induced changes in exosomal functions include effects on neurogenesis and neuroinflammation, which can lead to the appearance of various neuropsychiatric disorders such as schizophrenia, major depression, bipolar disorder, and Alzheimer's and Huntington's diseases. The current knowledge regarding the roles of exosomes in the pathophysiology of common mental disorders is discussed in this review. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Maternal obesity and metabolic (dysfunction) associated fatty liver disease in pregnancy: a comprehensive narrative review.

Author

Leca, Bianca M., Lagojda, Lukasz, Kite, Chris, Karteris, Emmanouil, Kassi, Eva, Randeva, Harpal S., and Kyrou, Ioannis

Subjects
FATTY liver, GESTATIONAL diabetes, PREGNANCY, PREGNANCY complications, PRENATAL care, OBESITY, NON-alcoholic fatty liver disease
Abstract

Obesity and metabolic-associated fatty liver disease (MAFLD) during pregnancy constitute significant problems for routine antenatal care, with increasing prevalence globally. Similar to obesity, MAFLD is associated with a higher risk for maternal complications (e.g. pre-eclampsia and gestational diabetes) and long-term adverse health outcomes for the offspring. However, MAFLD during pregnancy is often under-recognized, with limited management/treatment options. PubMed/MEDLINE, EMBASE, and Scopus were searched based on a search strategy for obesity and/or MAFLD in pregnancy to identify relevant papers up to 2024. This review summarizes the pertinent evidence on the relationship between maternal obesity and MAFLD during pregnancy. Key mechanisms implicated in the underlying pathophysiology linking obesity and MAFLD during pregnancy (e.g. insulin resistance and dysregulated adipokine secretion) are highlighted. Moreover, a diagnostic approach for MAFLD diagnosis during pregnancy and its complications are presented. Finally, promising relevant areas for future research are covered. Research progress regarding maternal obesity, MAFLD, and their impact on maternal and fetal/offspring health is expected to improve the relevant diagnostic methods and lead to novel treatments. Thus, routine practice could apply more personalized management strategies, incorporating individualized algorithms with genetic and/or multi-biomarker profiling to guide prevention, early diagnosis, and treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Non-Alcoholic Fatty Liver Disease and Echocardiographic Parameters of Left Ventricular Diastolic Function: A Systematic Review and Meta-Analysis

Author

Goliopoulou, Athina, primary, Theofilis, Panagiotis, additional, Oikonomou, Evangelos, additional, Anastasiou, Artemis, additional, Pantelidis, Panteleimon, additional, Gounaridi, Maria Ioanna, additional, Zakynthinos, Georgios E., additional, Katsarou, Ourania, additional, Kassi, Eva, additional, Lambadiari, Vaia, additional, Tousoulis, Dimitris, additional, Vavuranakis, Manolis, additional, and Siasos, Gerasimos, additional

Published
2023
Full Text
View/download PDF

24. Structural Speciation of Ti(IV)-(α-Hydroxycarboxylic Acid) Complexes in Metabolism-Related (Patho)Physiology—In Vitro Approaches to (Pre)Adipocyte Differentiation and Mineralization

Author

Tsave, Olga, primary, Iordanidou, Catherine, additional, Hatzidimitriou, Antonios, additional, Yavropoulou, Maria P., additional, Kassi, Eva N., additional, Nasiri-Ansari, Narjes, additional, Gabriel, Catherine, additional, and Salifoglou, Athanasios, additional

Published
2023
Full Text
View/download PDF

26. Data from Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors

Author

Grigoriou, Maria, primary, Banos, Aggelos, primary, Hatzioannou, Aikaterini, primary, Kloetgen, Andreas, primary, Kouzis, Panagiotis, primary, Aggouraki, Despoina, primary, Zakopoulou, Roubini, primary, Bamias, Giorgos, primary, Kassi, Eva, primary, Mavroudis, Dimitrios, primary, Bamias, Aristotelis, primary, Boumpas, Dimitrios T., primary, Tsirigos, Aristotelis, primary, Gogas, Helen, primary, Alissafi, Themis, primary, and Verginis, Panayotis, primary

Published
2023
Full Text
View/download PDF

27. Figure S1, Figure S2, Table S1 from Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors

Author

Grigoriou, Maria, primary, Banos, Aggelos, primary, Hatzioannou, Aikaterini, primary, Kloetgen, Andreas, primary, Kouzis, Panagiotis, primary, Aggouraki, Despoina, primary, Zakopoulou, Roubini, primary, Bamias, Giorgos, primary, Kassi, Eva, primary, Mavroudis, Dimitrios, primary, Bamias, Aristotelis, primary, Boumpas, Dimitrios T., primary, Tsirigos, Aristotelis, primary, Gogas, Helen, primary, Alissafi, Themis, primary, and Verginis, Panayotis, primary

Published
2023
Full Text
View/download PDF

30. Atherosclerotic and Cardio-Metabolic Diseases::From Molecular Basis to Therapeutic Advances

Author

Kassi, Eva, Kyrou, Ioannis, Randeva, Harpal S., Kassi, Eva, Kyrou, Ioannis, and Randeva, Harpal S.

Abstract

Cardiovascular diseases (CVDs) still remain the major cause of death worldwide; however, CVD-related mortality has been reduced due to lifestyle modification interventions, as well as novel pharmacological therapies and advances in cardiovascular surgery [...]

Published
2023

31. Vitrified Human Umbilical Arteries as Potential Grafts for Vascular Tissue Engineering

Author

Mallis, Panagiotis, Katsimpoulas, Michalis, Kostakis, Alkiviadis, Dipresa, Daniele, Korossis, Sotiris, Papapanagiotou, Aggeliki, Kassi, Eva, Stavropoulos-Giokas, Catherine, and Michalopoulos, Efstathios

Abstract

Background: The development of a biological based small diameter vascular graft (d < 6 mm), that can be properly stored over a long time period at − 196 °C, in order to directly be used to the patients, still remains a challenge. In this study the decellularized umbilical arteries (UAs) where vitrified, evaluated their composition and implanted to a porcine model, thus serving as vascular graft. Methods: Human UAs were decellularized using 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) and sodium dodecyl sulfate (SDS) detergents. Then, vitrified with vitrification solution 55 (VS55) solution, remained for 6 months in liquid nitrogen and their extracellular matrix composition was compared to conventionally cryopreserved UAs. Additionally, total hydroxyproline, sulphated glycosaminoglycan and DNA content were quantified in all samples. Finally, the vitrified umbilical arteries implanted as common carotid artery interposition graft to a porcine animal model. Results: Decellularized and vitrified UAs characterized by proper preservation of extracellular matrix proteins and tissue architecture, whereas conventionally cryopreserved samples exhibited a disorganized structure. Total hydroxyproline content was preserved, although sulphated glycosaminoglycan and DNA contents presented significantly alterations in all samples. Implanted UAs successfully recellularized and remodeled as indicated by the histological analysis. Conclusion: Decellularized and vitrified UAs retained their structure function properties and can be possible used as an alternative source for readily accessible small diameter vascular grafts.

Published
2024
Full Text
View/download PDF

33. What is the role of CHCHD2 in adrenal tumourigenesis?

Author

Karapanagioti, Angeliki, primary, Nasiri-Ansari, Narjes, additional, Moustogiannis, Athanasios, additional, Trigas, George C, additional, Zografos, Georgios, additional, Aggeli, Chrysanthi, additional, Kyriakopoulos, Georgios, additional, Choreftaki, Theodosia, additional, Philippou, Anastassios, additional, Kaltsas, Gregory, additional, Kassi, Eva, additional, and Angelousi, A, additional

Published
2023
Full Text
View/download PDF

41. Estrogen Receptor Subtypes Elicit a Distinct Gene Expression Profile of Endothelial-Derived Factors Implicated in Atherosclerotic Plaque Vulnerability

Author

Nasiri-Ansari, Narjes, primary, Spilioti, Eliana, additional, Kyrou, Ioannis, additional, Kalotychou, Vassiliki, additional, Chatzigeorgiou, Antonios, additional, Sanoudou, Despina, additional, Dahlman-Wright, Karin, additional, Randeva, Harpal S., additional, Papavassiliou, Athanasios G., additional, Moutsatsou, Paraskevi, additional, and Kassi, Eva, additional

Published
2022
Full Text
View/download PDF

47. Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research

Author

Tarantino, Giovanni, Flessa, Christina-Maria, Nasiri-Ansari, Narjes, Kyrou, Ioannis, Leca, Bianca M., Lianou, Maria, Chatzigeorgiou, Antonios, Kaltsas, Gregory, Kassi, Eva, Randeva, Harpal S., Tarantino, Giovanni, Flessa, Christina-Maria, Nasiri-Ansari, Narjes, Kyrou, Ioannis, Leca, Bianca M., Lianou, Maria, Chatzigeorgiou, Antonios, Kaltsas, Gregory, Kassi, Eva, and Randeva, Harpal S.

Abstract

A rapidly increasing incidence of non-alcoholic fatty liver disease (NAFLD) is noted worldwide due to the adoption of western-type lifestyles and eating habits. This makes the understanding of the molecular mechanisms that drive the pathogenesis of this chronic disease and the development of newly approved treatments of utmost necessity. Animal models are indispensable tools for achieving these ends. Although the ideal mouse model for human NAFLD does not exist yet, several models have arisen with the combination of dietary interventions, genetic manipulations and/or administration of chemical substances. Herein, we present the most common mouse models used in the research of NAFLD, either for the whole disease spectrum or for a particular disease stage (e.g., non-alcoholic steatohepatitis). We also discuss the advantages and disadvantages of each model, along with the challenges facing the researchers who aim to develop and use animal models for translational research in NAFLD. Based on these characteristics and the specific study aims/needs, researchers should select the most appropriate model with caution when translating results from animal to human.

Published
2022

48. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection?

Author

Androutsakos, Theodoros, Nasiri-Ansari, Narjes, Bakasis, Athanasios-Dimitrios, Kyrou, Ioannis, Efstathopoulos, Efstathios, Randeva, Harpal S., Kassi, Eva, Androutsakos, Theodoros, Nasiri-Ansari, Narjes, Bakasis, Athanasios-Dimitrios, Kyrou, Ioannis, Efstathopoulos, Efstathios, Randeva, Harpal S., and Kassi, Eva

Abstract

Non-alcoholic fatty liver disease (NAFLD) is an ‘umbrella’ term, comprising a spectrum ranging from benign, liver steatosis to non-alcoholic steatohepatitis, liver fibrosis and eventually cirrhosis and hepatocellular carcinoma. NAFLD has evolved as a major health problem in recent years. Discovering ways to prevent or delay the progression of NAFLD has become a global focus. Lifestyle modifications remain the cornerstone of NAFLD treatment, even though various pharmaceutical interventions are currently under clinical trial. Among them, sodium-glucose co-transporter type-2 inhibitors (SGLT-2i) are emerging as promising agents. Processes regulated by SGLT-2i, such as endoplasmic reticulum (ER) and oxidative stress, low-grade inflammation, autophagy and apoptosis are all implicated in NAFLD pathogenesis. In this review, we summarize the current understanding of the NAFLD pathophysiology, and specifically focus on the potential impact of SGLT-2i in NAFLD development and progression, providing current evidence from in vitro, animal and human studies. Given this evidence, further mechanistic studies would advance our understanding of the exact mechanisms underlying the pathogenesis of NAFLD and the potential beneficial actions of SGLT-2i in the context of NAFLD treatment.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results